WO1999028341A3 - Maintenance of smooth muscle integrity by morphogenic proteins - Google Patents
Maintenance of smooth muscle integrity by morphogenic proteins Download PDFInfo
- Publication number
- WO1999028341A3 WO1999028341A3 PCT/US1998/025398 US9825398W WO9928341A3 WO 1999028341 A3 WO1999028341 A3 WO 1999028341A3 US 9825398 W US9825398 W US 9825398W WO 9928341 A3 WO9928341 A3 WO 9928341A3
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- smooth muscle
- vascular
- occlusion
- protein
- muscle cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/475—Growth factors; Growth regulators
- C07K14/51—Bone morphogenetic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1875—Bone morphogenic factor; Osteogenins; Osteogenic factor; Bone-inducing factor
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
- C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
- C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
- C07K14/4702—Regulators; Modulating activity
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Gastroenterology & Hepatology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Toxicology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Immunology (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
Disclosed are compositions and methods for maintaining the integrity of smooth muscle, particularly vascular smooth muscle. Vascular diseases are characterized by an excessive build-up of vascular smooth muscle cells, resulting in an occlusion of a blood vessel, and/or by loss of elasticity in the blood vessels. Causes of blood vessel occlusion include smooth muscle cell proliferation and inflammatory responses. Inhibition of the proliferation of smooth muscle cells or inflammatory responses represents an effective treatment for vascular disorders, such as atherosclerosis and restenosis. Treatment may include administration of a morphogenic protein. The protein itself may be delivered to the site of vascular occlusion or the protein may be delivered by a vector, such as an adenoviral vector containing a DNA insert encoding a morphogenic protein. Such compositions and methods may also inhibit the responses of smooth muscle cells to various traumas, such as exposure to toxic agents. All of these treatmetns operate to preserve the cell phenotype by inhibiting an increase in extracellular matrix proteins, such as collagen, or by maintaining the normal balance of extracellular matrix proteins, such as Types I and III collagen.
Priority Applications (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CA002314423A CA2314423A1 (en) | 1997-12-04 | 1998-11-30 | Maintenance of smooth muscle integrity by morphogenic proteins |
| EP98961838A EP1037910A2 (en) | 1997-12-04 | 1998-11-30 | Maintenance of smooth muscle integrity by morphogenic proteins |
| AU17064/99A AU1706499A (en) | 1997-12-04 | 1998-11-30 | Maintenance of smooth muscle integrity by morphogenic proteins |
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US6769097P | 1997-12-04 | 1997-12-04 | |
| US60/067,690 | 1997-12-04 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| WO1999028341A2 WO1999028341A2 (en) | 1999-06-10 |
| WO1999028341A3 true WO1999028341A3 (en) | 1999-08-05 |
| WO1999028341A9 WO1999028341A9 (en) | 2001-05-31 |
Family
ID=22077719
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| PCT/US1998/025398 Ceased WO1999028341A2 (en) | 1997-12-04 | 1998-11-30 | Maintenance of smooth muscle integrity by morphogenic proteins |
Country Status (4)
| Country | Link |
|---|---|
| EP (1) | EP1037910A2 (en) |
| AU (1) | AU1706499A (en) |
| CA (1) | CA2314423A1 (en) |
| WO (1) | WO1999028341A2 (en) |
Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991005802A1 (en) * | 1989-10-17 | 1991-05-02 | Creative Biomolecules, Inc. | Osteogenic devices |
| WO1994003600A1 (en) * | 1992-07-31 | 1994-02-17 | Creative Biomolecules, Inc. | Morphogenic protein soluble complex and composition thereof |
| WO1995033502A1 (en) * | 1994-06-03 | 1995-12-14 | Creative Biomolecules, Inc. | Manufacture of autogenous replacement body parts |
| WO1996026737A1 (en) * | 1995-03-01 | 1996-09-06 | Creative Biomolecules, Inc. | Morphogen-induced dentine regeneration |
| WO1997007135A2 (en) * | 1995-08-14 | 1997-02-27 | Creative Biomolecules, Inc. | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| WO1997034626A1 (en) * | 1996-03-22 | 1997-09-25 | Creative Biomolecules, Inc. | Methods for enhancing functional recovery following central nervous system ischemia or trauma |
| WO1997041881A1 (en) * | 1996-05-06 | 1997-11-13 | Creative Biomolecules, Inc. | Morphogen treatment for chronic renal failure |
| WO1998034655A1 (en) * | 1997-02-07 | 1998-08-13 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
-
1998
- 1998-11-30 EP EP98961838A patent/EP1037910A2/en not_active Withdrawn
- 1998-11-30 WO PCT/US1998/025398 patent/WO1999028341A2/en not_active Ceased
- 1998-11-30 AU AU17064/99A patent/AU1706499A/en not_active Abandoned
- 1998-11-30 CA CA002314423A patent/CA2314423A1/en not_active Abandoned
Patent Citations (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO1991005802A1 (en) * | 1989-10-17 | 1991-05-02 | Creative Biomolecules, Inc. | Osteogenic devices |
| WO1994003600A1 (en) * | 1992-07-31 | 1994-02-17 | Creative Biomolecules, Inc. | Morphogenic protein soluble complex and composition thereof |
| WO1995033502A1 (en) * | 1994-06-03 | 1995-12-14 | Creative Biomolecules, Inc. | Manufacture of autogenous replacement body parts |
| WO1996026737A1 (en) * | 1995-03-01 | 1996-09-06 | Creative Biomolecules, Inc. | Morphogen-induced dentine regeneration |
| WO1997007135A2 (en) * | 1995-08-14 | 1997-02-27 | Creative Biomolecules, Inc. | Binding of osteogenic protein-i (op-1) and analogs thereof to the cell surface receptor alk-1 and analogs thereof |
| WO1997034626A1 (en) * | 1996-03-22 | 1997-09-25 | Creative Biomolecules, Inc. | Methods for enhancing functional recovery following central nervous system ischemia or trauma |
| WO1997041881A1 (en) * | 1996-05-06 | 1997-11-13 | Creative Biomolecules, Inc. | Morphogen treatment for chronic renal failure |
| WO1998034655A1 (en) * | 1997-02-07 | 1998-08-13 | Stryker Corporation | Matrix-free osteogenic devices, implants and methods of use thereof |
Also Published As
| Publication number | Publication date |
|---|---|
| EP1037910A2 (en) | 2000-09-27 |
| AU1706499A (en) | 1999-06-16 |
| WO1999028341A2 (en) | 1999-06-10 |
| CA2314423A1 (en) | 1999-06-10 |
| WO1999028341A9 (en) | 2001-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Johnson et al. | The activated mesangial cell: a glomerular" myofibroblast"? | |
| Schmidt et al. | Identification of hydrogen peroxide as the relevant messenger in the activation pathway of transcription factor NF-κB | |
| de Cavanagh et al. | Superoxide dismutase and glutathione peroxidase activities are increased by enalapril and captopril in mouse liver | |
| WO1996011266A3 (en) | Method for inhibiting smooth muscle cell proliferation and oligonucleotides for use therein | |
| IL187254A (en) | ANTISENSE NUCLEOTIDES, COMPOSITIONS COMPRISING THEREOF AND THEIR USE IN MODULATING ACTIVATION OF NF-kB | |
| WO1999040197A3 (en) | Variants of the angiogenic factor vascular endothelial cell growth factor: vegf | |
| BR0315645A (en) | Actrib fusion polypeptides and their uses | |
| Vance et al. | Heat shock of rabbit synovial fibroblasts increases expression of mRNAs for two metalloproteinases, collagenase and stromelysin. | |
| NO981810L (en) | Compositions and Methods for Treating Bone Failure Conditions | |
| CY2241B1 (en) | Fluoxetine pharmaceutical formulations | |
| Lopez-Farre et al. | Role of nitric oxide in the control of apoptosis in the microvasculature | |
| Yasui et al. | Coordinate regulation of type IX and type II collagen synthesis during growth of chick chondrocytes in retinoic acid or 5-bromo-2'-deoxyuridine. | |
| WO2000038785A3 (en) | Methods for treating certain diseases using naaladase inhibitors | |
| Schalling et al. | Rapid increase in enzyme and peptide mRNA in sympathetic ganglia after electrical stimulation in humans. | |
| Dayal et al. | Role of redox reactions in the vascular phenotype of hyperhomocysteinemic animals | |
| WO1999054460A3 (en) | Human nucleic acid sequences of normal bladder tissue | |
| AU690853B2 (en) | Peptide for inhibiting blood triglyceride level rise and inhibitor for blood triglyceride level rise comprising the peptide as active ingredient | |
| WO1997026322A3 (en) | Methods and compositions for inhibiting hexokinase | |
| MX9701816A (en) | Bacteria strains, and pharmaceutical composition containing such strains, and use thereof to prevent and to treat illnesses associated with biliary acids altered metabolism or caused thereby. | |
| HUP9901597A3 (en) | Method of killing target cells in harvested cell populations with one or more immuno-toxins | |
| WO1997010334A3 (en) | Ribozyme therapy for the treatment and/or prevention of restenosis | |
| WO1996040743A3 (en) | Inhibitors of factor xa | |
| HK1040402A1 (en) | Compositions and methods using lactadherin or variants thereof | |
| CA2347178A1 (en) | Methods of inhibiting smooth muscle cell proliferation and preventing restenosis with a vector expressing rb2/p130 | |
| IL132310A0 (en) | Cytomodulating lipophilic peptides for modulating immune system activity and inhibiting inflammation |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| AK | Designated states |
Kind code of ref document: A2 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| AK | Designated states |
Kind code of ref document: A3 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: A3 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| 121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
| DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
| ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2000 523232 Kind code of ref document: A Format of ref document f/p: F |
|
| ENP | Entry into the national phase |
Ref document number: 2314423 Country of ref document: CA Ref country code: CA Ref document number: 2314423 Kind code of ref document: A Format of ref document f/p: F |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 17064/99 Country of ref document: AU |
|
| WWE | Wipo information: entry into national phase |
Ref document number: 1998961838 Country of ref document: EP |
|
| WWP | Wipo information: published in national office |
Ref document number: 1998961838 Country of ref document: EP |
|
| AK | Designated states |
Kind code of ref document: C2 Designated state(s): AU CA JP US |
|
| AL | Designated countries for regional patents |
Kind code of ref document: C2 Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE |
|
| COP | Corrected version of pamphlet |
Free format text: PAGES 1/10-10/10, DRAWINGS, REPLACED BY NEW PAGES 1/11-11/11; DUE TO LATE TRANSMITTAL BY THE RECEIVING OFFICE |
|
| WWW | Wipo information: withdrawn in national office |
Ref document number: 1998961838 Country of ref document: EP |